Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC trimmed its position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 26.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 340,627 shares of the company’s stock after selling 125,272 shares during the quarter. ArrowMark Colorado Holdings LLC owned about 0.45% of Kiniksa Pharmaceuticals International worth $13,227,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Savant Capital LLC acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter worth approximately $398,000. GSA Capital Partners LLP lifted its stake in Kiniksa Pharmaceuticals International by 281.9% during the 3rd quarter. GSA Capital Partners LLP now owns 77,984 shares of the company’s stock valued at $3,028,000 after acquiring an additional 57,566 shares during the period. Aberdeen Group plc acquired a new stake in Kiniksa Pharmaceuticals International during the 3rd quarter valued at approximately $6,163,000. Fisher Asset Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 176.1% in the 3rd quarter. Fisher Asset Management LLC now owns 282,288 shares of the company’s stock valued at $10,961,000 after acquiring an additional 180,029 shares during the last quarter. Finally, Essex Investment Management Co. LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 44.3% in the 3rd quarter. Essex Investment Management Co. LLC now owns 247,301 shares of the company’s stock valued at $9,603,000 after acquiring an additional 75,864 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KNSA. Wedbush raised their target price on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Finally, Canaccord Genuity Group initiated coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, February 19th. They set a “buy” rating and a $62.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus target price of $55.29.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $45.78 on Friday. The stock has a market capitalization of $3.50 billion, a price-to-earnings ratio of 61.86 and a beta of 0.06. The firm’s 50 day simple moving average is $43.83 and its 200-day simple moving average is $40.72. Kiniksa Pharmaceuticals International, plc has a 12 month low of $18.25 and a 12 month high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.12). Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The firm had revenue of $202.13 million during the quarter, compared to analyst estimates of $200.86 million. During the same quarter in the prior year, the firm earned ($0.12) earnings per share. The business’s revenue for the quarter was up 65.0% on a year-over-year basis. Analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, CFO Mark Ragosa sold 17,845 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $43.28, for a total transaction of $772,331.60. Following the sale, the chief financial officer directly owned 12,086 shares of the company’s stock, valued at $523,082.08. This represents a 59.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Barry D. Quart sold 20,129 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $41.51, for a total value of $835,554.79. Following the sale, the director owned 12,546 shares in the company, valued at $520,784.46. This trade represents a 61.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 80,782 shares of company stock valued at $3,458,916. Corporate insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.